Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$7.57
+1.0%
$8.06
$5.20
$10.67
$1.03B1.161.37 million shs1.01 million shs
Epizyme, Inc. stock logo
EPZM
Epizyme
$1.47
$1.47
$0.41
$5.80
$247.44M-0.413.23 million shs7,960 shs
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
$329.83
$327.01
$158.38
$329.99
$12.58B1.18832,048 shs5 shs
Principia Biopharma Inc. stock logo
PRNB
Principia Biopharma
$100.05
$100.05
$25.35
$101.89
$3.32B0.86729,676 shsN/A
Ra Pharmaceuticals Inc stock logo
RARX
Ra Pharmaceuticals
$47.99
$47.99
$19.64
$48.02
$2.27B1.051.16 million shs30,200 shs
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
0.00%-12.43%-5.31%-3.12%+38.32%
Epizyme, Inc. stock logo
EPZM
Epizyme
0.00%0.00%0.00%0.00%0.00%
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
0.00%0.00%0.00%0.00%0.00%
Principia Biopharma Inc. stock logo
PRNB
Principia Biopharma
0.00%0.00%0.00%0.00%0.00%
Ra Pharmaceuticals Inc stock logo
RARX
Ra Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
3.1101 of 5 stars
3.51.00.00.02.50.82.5
Epizyme, Inc. stock logo
EPZM
Epizyme
N/AN/AN/AN/AN/AN/AN/AN/A
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Principia Biopharma Inc. stock logo
PRNB
Principia Biopharma
N/AN/AN/AN/AN/AN/AN/AN/A
Ra Pharmaceuticals Inc stock logo
RARX
Ra Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
3.00
Buy$11.5052.00% Upside
Epizyme, Inc. stock logo
EPZM
Epizyme
0.00
N/AN/AN/A
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
0.00
N/AN/AN/A
Principia Biopharma Inc. stock logo
PRNB
Principia Biopharma
0.00
N/AN/AN/A
Ra Pharmaceuticals Inc stock logo
RARX
Ra Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$235.13M4.35$0.31 per share24.61$2.68 per share2.82
Epizyme, Inc. stock logo
EPZM
Epizyme
$37.43M6.61N/AN/A($0.54) per share-2.72
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
$654K19,239.07N/AN/A$33.24 per share9.92
Principia Biopharma Inc. stock logo
PRNB
Principia Biopharma
$35.16M94.50N/AN/A$10.95 per share9.14
Ra Pharmaceuticals Inc stock logo
RARX
Ra Pharmaceuticals
$3M757.11N/AN/A$5.56 per share8.63
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$5.75M$0.2827.0213.51N/A16.11%14.27%9.93%7/30/2025 (Estimated)
Epizyme, Inc. stock logo
EPZM
Epizyme
-$251.12M-$1.72N/AN/AN/A-391.90%-2,459.33%-69.74%N/A
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
-$433.68M-$11.72N/AN/AN/AN/A-31.63%-30.38%N/A
Principia Biopharma Inc. stock logo
PRNB
Principia Biopharma
-$53.79M-$2.09N/AN/AN/AN/A-23.08%-21.11%N/A
Ra Pharmaceuticals Inc stock logo
RARX
Ra Pharmaceuticals
-$102.69M-$2.31N/AN/AN/AN/A-44.61%-41.60%N/A

Latest PRNB, KRTX, EPZM, AUPH, and RARX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$0.08$0.16+$0.08$0.16$61.06 million$62.47 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
N/AN/AN/AN/AN/A
Epizyme, Inc. stock logo
EPZM
Epizyme
N/AN/AN/AN/AN/A
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
N/AN/AN/AN/AN/A
Principia Biopharma Inc. stock logo
PRNB
Principia Biopharma
N/AN/AN/AN/AN/A
Ra Pharmaceuticals Inc stock logo
RARX
Ra Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
0.16
5.93
5.26
Epizyme, Inc. stock logo
EPZM
Epizyme
N/A
5.35
5.19
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
N/A
19.31
19.31
Principia Biopharma Inc. stock logo
PRNB
Principia Biopharma
N/A
17.01
17.01
Ra Pharmaceuticals Inc stock logo
RARX
Ra Pharmaceuticals
0.01
14.78
14.79

Institutional Ownership

CompanyInstitutional Ownership
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
36.83%
Epizyme, Inc. stock logo
EPZM
Epizyme
76.45%
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
N/A
Principia Biopharma Inc. stock logo
PRNB
Principia Biopharma
95.54%
Ra Pharmaceuticals Inc stock logo
RARX
Ra Pharmaceuticals
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
300135.10 million118.62 millionOptionable
Epizyme, Inc. stock logo
EPZM
Epizyme
250168.33 million128.97 millionOptionable
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
33938.15 million33.16 millionOptionable
Principia Biopharma Inc. stock logo
PRNB
Principia Biopharma
6533.21 millionN/ANot Optionable
Ra Pharmaceuticals Inc stock logo
RARX
Ra Pharmaceuticals
7247.33 millionN/AOptionable

Recent News About These Companies

Antibiotic Use Increases the Risk of Rheumatoid Arthritis
Rheumatoid Arthritis and RA-ILD Linked to Increased Lung Cancer Risk
RA: Discount Continues To Leave Some Opportunity

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aurinia Pharmaceuticals stock logo

Aurinia Pharmaceuticals NASDAQ:AUPH

$7.57 +0.08 (+1.01%)
Closing price 07/3/2025 03:58 PM Eastern
Extended Trading
$7.56 0.00 (-0.01%)
As of 07/3/2025 04:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Epizyme stock logo

Epizyme NASDAQ:EPZM

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Karuna Therapeutics stock logo

Karuna Therapeutics NASDAQ:KRTX

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Principia Biopharma stock logo

Principia Biopharma NASDAQ:PRNB

Principia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immunology and oncology. The company is developing PRN1008, an inhibitor that is in Phase III clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial to treat immune thrombocytopenic purpura. It is also developing PRN2246/SAR442168, an inhibitor, which has completed Phase I clinical trial for treating multiple sclerosis (MS) and other central nervous system (CNS) diseases; PRN1371, a drug candidate that is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome. The company has a collaboration agreement with Genzyme Corporation to develop relapsing and progressive MS and other diseases of the CNS. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California.

Ra Pharmaceuticals stock logo

Ra Pharmaceuticals NASDAQ:RARX

Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is Zilucoplan, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of generalized myasthenia gravis (gMG); has completed Phase II clinical trial for treating paroxysmal nocturnal hemoglobinuria (PNH); and has completed Phase Ib clinical trial to treat patients with renal impairment. The company's pre-clinical programs include Factor D inhibition for treating C3 glomerulonephritis and dense deposit disease; and inhibitors of other complement factors for renal, autoimmune, and central nervous system diseases. It has collaboration and license agreement with Merck & Co., Inc. to identify orally available cyclic peptides for non-complement program targets, and provide research and development services. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.